Aarti Pharmalabs Limited
NSE: AARTIPHARM BSE: AARTIPHARM
Prev Close
926.35
Open Price
928.7
Volume
224,869
Today Low / High
913.85 / 941.85
52 WK Low / High
557.05 / 971
Range
894 - 989
Prev Close
926.55
Open Price
934.65
Volume
26,465
Today Low / High
913.95 / 938.8
52 WK Low / High
550.25 / 971.5
Range
889 - 982
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 941.45 (target range: 894 - 989), reflecting a change of 15.1 (1.63005%). On the BSE, it is listed at 935.4 (target range: 889 - 982), showing a change of 8.85 (0.95516%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Aarti Pharmalabs Limited Graph
Aarti Pharmalabs Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Aarti Pharmalabs Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 941.45, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
Scenario | Price | Target | Range |
---|---|---|---|
Bullish Scenario | 935.40 | 944.75 | 850.28 - 1,039.23 |
954.11 | 763.29 - 1,144.93 | ||
963.46 | 674.42 - 1,252.50 | ||
Bearish Scenario | 935.40 | 926.05 | 833.44 - 1,018.65 |
916.69 | 733.35 - 1,100.03 | ||
907.34 | 635.14 - 1,179.54 |
Overview of Aarti Pharmalabs Limited
ISIN
INE0LRU01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
320,982
Market Cap
83,957,850,833
Last Dividend
2.5
Official Website
IPO Date
2023-01-30
DCF Diff
-1,148.29
DCF
1,906
Financial Ratios Every Investor Needs
Stock Dividend of AARTIPHARM
Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|---|
2025-09-15 | September 15, 25 | 2.5 | 2.5 | 2025-09-15 | 2025-10-20 | |
2025-02-14 | February 14, 25 | 2.5 | 2.5 | 2025-02-14 | 2025-03-07 | |
2024-07-31 | July 31, 24 | 1 | 1 | 2024-07-31 | 2024-09-02 | |
2024-02-16 | February 16, 24 | 2 | 2 | 2024-02-19 | 2024-03-08 |
Annual Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 2,115.07 Cr | 1,127.88 Cr | 987.20 Cr | 0.4667 | 0.00 Cr | 0.00 Cr | 377.47 Cr | 272.40 Cr | 30.06 | 464.37 Cr | 0.1288 |
2024-03-31 | 1,815.51 Cr | 1,424.71 Cr | 390.80 Cr | 0.2153 | 8.37 Cr | 12.39 Cr | 312.81 Cr | 216.90 Cr | 23.93 | 390.94 Cr | 0.1195 |
2023-03-31 | 1,945.23 Cr | 1,531.36 Cr | 413.87 Cr | 0.2128 | 13.96 Cr | 14.44 Cr | 279.51 Cr | 193.49 Cr | 21.35 | 344.37 Cr | 0.0995 |
2022-03-31 | 1,192.03 Cr | 879.70 Cr | 312.33 Cr | 0.2620 | 0.00 Cr | 1.51 Cr | 164.83 Cr | 122.25 Cr | 13.49 | 197.84 Cr | 0.1026 |
2021-03-31 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.0000 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -0.18 | 0.00 Cr | 0.0000 |
Annual Financials Balance Sheet
Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 8.65 Cr | 2,906.41 Cr | 916.50 Cr | 1,989.9064 Cr | 413.12 Cr | 404.47 Cr | 587.58 Cr | 1,410.70 Cr | 0.00 Cr | 0.00 Cr | 29.24 Cr | 657.0495 Cr |
2024-03-31 | 23.63 Cr | 2,582.11 Cr | 825.07 Cr | 1,757.0400 Cr | 285.25 Cr | 261.62 Cr | 642.86 Cr | 1,105.45 Cr | 0.00 Cr | 0.00 Cr | 36.78 Cr | 694.3891 Cr |
2023-03-31 | 12.12 Cr | 2,244.02 Cr | 685.54 Cr | 1,558.4866 Cr | 215.31 Cr | 203.19 Cr | 602.04 Cr | 988.57 Cr | 0.00 Cr | 0.00 Cr | -6.03 Cr | 600.6234 Cr |
2022-03-31 | 83.27 Cr | 2,039.90 Cr | 653.42 Cr | 1,386.4778 Cr | 341.40 Cr | 258.13 Cr | 475.45 Cr | 945.31 Cr | 0.00 Cr | -1.00 Cr | 32.23 Cr | 580.6649 Cr |
2021-03-31 | 0.25 Cr | 0.25 Cr | 0.02 Cr | 0.2267 Cr | 0.02 Cr | -0.23 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.0219 Cr |
Annual Financials Cash Flow Statement
Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 331.5615 Cr | -413.8977 Cr | 65.4350 Cr | -70.4759 Cr | -16.9012 Cr | 6.7337 Cr | -443.8784 Cr | 272.4048 Cr | 127.8608 Cr | -31.7191 Cr | 55.2790 Cr |
2024-03-31 | 216.3546 Cr | -214.5644 Cr | 9.7235 Cr | 17.5695 Cr | 11.5137 Cr | 23.6349 Cr | -155.6042 Cr | 216.9020 Cr | 49.9934 Cr | -18.1252 Cr | -39.6600 Cr |
2023-03-31 | 250.1154 Cr | -157.8030 Cr | -163.4646 Cr | 130.4585 Cr | -71.1522 Cr | 12.1212 Cr | -119.6569 Cr | 260.7747 Cr | -124.2877 Cr | -18.1252 Cr | -126.6600 Cr |
2022-03-31 | -43.7038 Cr | -138.7389 Cr | 260.3834 Cr | -184.8558 Cr | 83.0234 Cr | 83.2734 Cr | -141.1520 Cr | 155.3804 Cr | 272.3422 Cr | 0.0000 Cr | -55.9920 Cr |
2021-03-31 | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr | 0.2500 Cr | 0.0000 Cr | -0.0046 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr |
Quarterly Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|
2025-06-30 | 386.19 Cr | 169.41 Cr | 216.79 Cr | 0.5613 | 72.45 Cr | 49.50 Cr | 5.46 | 95.04 Cr | 0.1282 |
2025-03-31 | 563.78 Cr | 278.75 Cr | 285.03 Cr | 0.5056 | 122.81 Cr | 88.34 Cr | 9.75 | 144.54 Cr | 0.1567 |
2024-12-31 | 537.78 Cr | 275.31 Cr | 262.47 Cr | 0.4881 | 105.57 Cr | 73.99 Cr | 8.16 | 133.64 Cr | 0.1376 |
2024-09-30 | 458.03 Cr | 235.58 Cr | 222.45 Cr | 0.4857 | 72.79 Cr | 54.62 Cr | 6.03 | 98.16 Cr | 0.1193 |
2024-06-30 | 555.49 Cr | 397.64 Cr | 157.85 Cr | 0.2842 | 76.29 Cr | 55.45 Cr | 6.12 | 98.68 Cr | 0.0998 |
Quarterly Financials Balance Sheet
Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 8.65 Cr | 47.56 Cr | 56.21 Cr | 576.42 Cr | 587.58 Cr | 1,322.17 Cr | 1,410.70 Cr | 2,906.41 Cr | 916.50 Cr |
2024-12-31 | 0.00 Cr | 0.00 Cr | 99.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,856.73 Cr |
2024-09-30 | 41.35 Cr | 58.16 Cr | 99.51 Cr | 434.38 Cr | 719.80 Cr | 1,376.67 Cr | 1,228.35 Cr | 2,776.51 Cr | 919.79 Cr |
2024-06-30 | -94.32 Cr | 188.63 Cr | 94.32 Cr | 0.00 Cr | 0.00 Cr | 94.32 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-03-31 | 23.63 Cr | 70.40 Cr | 94.45 Cr | 531.46 Cr | 642.86 Cr | 1,345.64 Cr | 1,105.45 Cr | 2,582.11 Cr | 825.07 Cr |
Quarterly Financials Cash Flow Statement
Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 88.34 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-12-31 | 73.99 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-09-30 | 54.62 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-06-30 | 55.45 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-03-31 | 65.25 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
Date | Label | Split Ratio |
---|---|---|
No split history data available. |
Similar Stocks: Drug Manufacturers - Specialty & Generic
Company Name | Symbol | Price | Market Cap | Volume |
---|---|---|---|---|
Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,609.00 | ₹3,860,441,520,000.00 | ₹1,626,288.00 |
Divi's Laboratories Limited | DIVISLAB | ₹6,050.50 | ₹1,606,220,184,500.00 | ₹63,569.00 |
Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,530.90 | ₹1,195,015,450,500.00 | ₹135,292.00 |
Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,300.70 | ₹1,082,646,847,453.00 | ₹954,623.00 |
Mankind Pharma Limited | MANKIND | ₹2,588.90 | ₹1,068,589,227,622.00 | ₹92,714.00 |
Zydus Lifesciences Limited | ZYDUSLIFE | ₹1,036.15 | ₹1,042,605,214,500.00 | ₹296,469.00 |
Lupin Limited | LUPIN | ₹2,040.60 | ₹932,054,253,000.00 | ₹325,910.00 |
Alkem Laboratories Limited | ALKEM | ₹5,506.50 | ₹658,384,672,500.00 | ₹126,076.00 |
Aurobindo Pharma Limited | AUROPHARMA | ₹1,100.80 | ₹639,346,841,600.00 | ₹870,057.00 |
Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,100.20 | ₹592,678,540,200.00 | ₹402,431.00 |
Laurus Labs Limited | LAURUSLABS | ₹893.00 | ₹482,063,725,000.00 | ₹396,445.00 |
Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
Cohance Lifesciences Limited | COHANCE | ₹982.00 | ₹375,680,801,856.00 | ₹57,880.00 |
Ipca Laboratories Limited | IPCALAB | ₹1,309.10 | ₹332,123,906,400.00 | ₹70,482.00 |
Ajanta Pharma Limited | AJANTPHARM | ₹2,555.50 | ₹319,273,948,000.00 | ₹14,183.00 |
J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,681.60 | ₹263,331,833,600.00 | ₹78,315.00 |
Piramal Enterprises Limited | PEL | ₹1,132.00 | ₹256,599,496,000.00 | ₹946,023.00 |
Wockhardt Limited | WOCKPHARMA | ₹1,511.10 | ₹245,530,782,791.00 | ₹113,354.00 |
Eris Lifesciences Limited | ERIS | ₹1,664.90 | ₹226,771,034,300.00 | ₹30,477.00 |
AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,024.50 | ₹225,612,500,000.00 | ₹7,781.00 |
Neuland Laboratories Limited | NEULANDLAB | ₹15,790.00 | ₹202,584,121,000.00 | ₹31,902.00 |
Alembic Pharmaceuticals Limited | APLLTD | ₹960.00 | ₹188,700,480,000.00 | ₹226,418.00 |
Jubilant Pharmova Limited | JUBLPHARMA | ₹1,124.40 | ₹179,095,556,400.00 | ₹61,537.00 |
Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,266.90 | ₹172,310,922,730.00 | ₹101,864.00 |
NATCO Pharma Limited | NATCOPHARM | ₹853.50 | ₹152,870,385,000.00 | ₹325,818.00 |
Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
Granules India Limited | GRANULES | ₹531.25 | ₹128,904,625,000.00 | ₹689,565.00 |
Procter & Gamble Health Limited | PGHL | ₹6,267.00 | ₹104,028,439,800.00 | ₹5,131.00 |
Aarti Pharmalabs Limited | AARTIPHARM | ₹936.70 | ₹84,895,902,062.00 | ₹207,949.00 |
Strides Pharma Science Limited | STAR | ₹887.40 | ₹81,794,053,980.00 | ₹143,336.00 |
Shilpa Medicare Limited | SHILPAMED | ₹828.90 | ₹81,058,877,010.00 | ₹111,223.00 |
FDC Limited | FDC | ₹465.80 | ₹75,836,898,000.00 | ₹37,634.00 |
Suven Life Sciences Limited | SUVEN | ₹226.01 | ₹49,279,377,929.00 | ₹85,787.00 |
Innova Captab Limited | INNOVACAP | ₹856.60 | ₹49,018,875,038.00 | ₹10,615.00 |
Aarti Drugs Limited | AARTIDRUGS | ₹513.40 | ₹46,858,018,000.00 | ₹133,136.00 |
Sun Pharma Advanced Research Company Limited | SPARC | ₹143.75 | ₹46,650,037,500.00 | ₹131,516.00 |
Sequent Scientific Limited | SEQUENT | ₹183.98 | ₹46,056,633,300.00 | ₹295,810.00 |
RPG Life Sciences Limited | RPGLIFE | ₹2,385.30 | ₹39,450,476,700.00 | ₹8,145.00 |
Gufic Biosciences Limited | GUFICBIO | ₹365.95 | ₹36,696,734,100.00 | ₹21,786.00 |
Orchid Pharma Limited | ORCHPHARMA | ₹707.00 | ₹35,858,403,700.00 | ₹36,027.00 |
Unichem Laboratories Limited | UNICHEMLAB | ₹504.15 | ₹35,495,084,070.00 | ₹8,735.00 |
IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹118.86 | ₹34,888,619,220.00 | ₹11,214,307.00 |
Solara Active Pharma Sciences Limited | SOLARA | ₹676.15 | ₹32,558,650,950.00 | ₹52,292.00 |
Hikal Limited | HIKAL | ₹260.75 | ₹32,150,735,750.00 | ₹115,051.00 |
Morepen Laboratories Limited | MOREPENLAB | ₹53.52 | ₹29,326,498,080.00 | ₹1,745,659.00 |
Indoco Remedies Limited | INDOCO | ₹294.30 | ₹27,148,556,970.00 | ₹140,867.00 |
Alembic Limited | ALEMBICLTD | ₹104.84 | ₹26,921,024,775.00 | ₹231,892.00 |
Key Executives
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1964
Gender: female
Year Born: 1975
Gender: Not Specified
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
FAQs about Aarti Pharmalabs Limited
The CEO is Hetal Gogri Gala.
The current price is ₹926.35.
The range is ₹557.05-971.
The market capitalization is ₹8,395.79 crores.
The dividend yield is 0.27%.
The P/E ratio is 31.52.
The company operates in the Healthcare sector.
Overview of Aarti Pharmalabs Limited (ISIN: INE0LRU01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹8,395.79 crores and an average daily volume of 320,982 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹2.5.